Per Lindell

Per Lindell is an experienced professional in the biotechnology and pharmaceutical industries, currently serving as the part-time CEO of a stealth biotech startup focused on developing long-duration drugs for retinal disease. Lindell has been the Managing Director of Novadigm Consulting Group since 2011, providing comprehensive consulting services in drug design, clinical development, and corporate strategy. Additional roles include being a member of the Harvard Business Review Advisory Council and serving as an AV Expert for Alumni Ventures. Lindell's prior experience encompasses leadership positions at IBM Global Business Services, Easton Associates, Genta Inc., and Metaphore Pharmaceuticals, focusing on corporate development and strategic consulting. Lindell holds a Doctor of Science degree from the Massachusetts Institute of Technology and a Master of Science in Chemical Engineering from KTH Royal Institute of Technology.